Patents Assigned to Fred Hutchinson Cancer Research Center
  • Patent number: 10815290
    Abstract: Single chain, multimerized, and/or glycosylated NKG2D decoys are described. The NKG2D decoys have high affinity and avidity for surface bound and soluble NKG2D ligands and can be used to (i) identify NKG2D ligands; (ii) treat cancer, graft vs. host disease (GVHD), and inflammatory conditions; and (iii) potentiate an immune response against a vaccine as well as many other potential uses.
    Type: Grant
    Filed: November 10, 2016
    Date of Patent: October 27, 2020
    Assignee: FRED HUTCHINSON CANCER RESEARCH CENTER
    Inventors: Mesfin Gewe, Roland K. Strong, Martin Prlic, Peter Rupert, Thomas Spies, Veronika Spies
  • Patent number: 10813949
    Abstract: Uses of expanded cord blood hematopoietic stem/progenitor cells (HSPC) are described. Examples include to reduce transplant rejection, to induce immune tolerance, to reduce total parenteral nutrition (TPN) feeding, opioid use, mucositis, and hospitalization following a medical procedure and to reduce graft versus host disease (GVHD) following an allogeneic transplant.
    Type: Grant
    Filed: December 5, 2016
    Date of Patent: October 27, 2020
    Assignee: FRED HUTCHINSON CANCER RESEARCH CENTER
    Inventor: Colleen Delaney
  • Publication number: 20200330603
    Abstract: The present disclosure provides compositions and methods for renal therapy. In various aspects, the present disclosure provides a composition comprising a knotted peptide, wherein upon administration to a subject the knotted peptide homes, targets, is directed to, accumulates in, migrates to, is retained by, and/or binds to renal tissue of the subject. In various aspects, the composition further comprises an active agent coupled to the knotted peptide. The composition, when administered to the subject, may induce protective preconditioning or acquired cytoresistance.
    Type: Application
    Filed: December 9, 2016
    Publication date: October 22, 2020
    Applicant: FRED HUTCHINSON CANCER RESEARCH CENTER
    Inventors: Richard A. Zager, James M. Olson, Emily J. Girard, Colin E. Correnti, Theo L. Sottero
  • Patent number: 10806756
    Abstract: The present disclosure provides compositions and methods for the delivery of immune cells to treat un-resectable or non-resected tumor cells and tumor relapse. The compositions comprise (i) a structure comprising an injectable polymer or scaffold comprising pores; (ii) lymphocytes disposed within the structure, (iii) at least one lymphocyte-adhesion moiety associated with the structure; and (iv) at least one lymphocyte-activating moiety associated with the structure, and optionally an immune stimulant.
    Type: Grant
    Filed: October 10, 2018
    Date of Patent: October 20, 2020
    Assignee: FRED HUTCHINSON CANCER RESEARCH CENTER
    Inventor: Matthias Stephan
  • Publication number: 20200297696
    Abstract: The present disclosure provides methods of treating a patient comprising administering a p38 inhibitor for the treatment of FSHD. In some embodiments, the present methods comprise using one or more p38 inhibitors as a therapeutic agent for the treatment of FSHD patients including patients who are being treated with one or more palliative treatments such as therapy and/or agents which lead to increased muscle mass.
    Type: Application
    Filed: November 16, 2018
    Publication date: September 24, 2020
    Applicants: Saint Louis University, Fred Hutchinson Cancer Research Center
    Inventors: Francis M. SVERDRUP, Stephen J. TAPSCOTT, Jonathan OLIVA, Amy E. CAMPBELL, Marvin J. MEYERS
  • Patent number: 10780118
    Abstract: The present invention provides nucleic acids, vectors, host cells, methods and compositions to confer and/or augment immune responses mediated by cellular immunotherapy, such as by adoptively transferring CD8+ central memory T cells or combinations of central memory T cells with CD4+ T cells that are genetically modified to express a chimeric receptor. In embodiments the genetically modified host cell comprises a nucleic acid comprising a polynucleotide coding for a ligand binding domain, a polynucleotide comprising a customized spacer region, a polynucleotide comprising a transmembrane domain, and a polynucleotide comprising an intracellular signaling domain. It has been surprisingly found that the length of the spacer region can affects the ability of chimeric receptor modified T cells to recognize target cells in vitro and affects in vivo efficacy of the chimeric receptor modified T cells. Pharmaceutical formulations produced by the method, and methods of using the same, are also described.
    Type: Grant
    Filed: August 20, 2013
    Date of Patent: September 22, 2020
    Assignees: Fred Hutchinson Cancer Research Center, Seattle Children's Hospital
    Inventors: Michael C. Jensen, Stanley R. Riddell, Michael Hudecek
  • Publication number: 20200289565
    Abstract: Provided herein are combination therapies involving administration of an immunotherapy involving a cell therapy, such as a T cell therapy, and an inhibitor of gamma secretase. Also provided are methods for engineering, preparing, and producing the cells, compositions containing the cells and/or gamma secretase inhibitor, and kits and devices containing and for using, producing and administering the cells and/or gamma secretase inhibitor, such as in accord with the provided combination therapy methods.
    Type: Application
    Filed: November 6, 2018
    Publication date: September 17, 2020
    Applicants: Juno Therapeutics, Inc., Fred Hutchinson Cancer Research Center
    Inventors: Damian J. GREEN, Stanley R. RIDDELL, Melissa WORKS
  • Patent number: 10752915
    Abstract: In one aspect, the present invention provides an intron-modified capsid expression cassette useful for generating adeno-associated virus (AAV) vector particles. In another aspect, the present invention provides a method of reducing the immune response in a mammalian subject undergoing treatment with an AAV vector.
    Type: Grant
    Filed: March 17, 2016
    Date of Patent: August 25, 2020
    Assignee: Fred Hutchinson Cancer Research Center
    Inventors: Arthur Dusty Miller, Christine L. Halbert, Michael J. Metzger
  • Patent number: 10736918
    Abstract: The present invention provides nucleic acids, vectors, host cells, methods and compositions to confer and/or augment immune responses mediated by cellular immunotherapy, such as by adoptively transferring CD8+ central memory T cells or combinations of central memory T cells with CD4+ T cells that are genetically modified to express a chimeric receptor. In embodiments the genetically modified host cell comprises a nucleic acid comprising a polynucleotide coding for a ligand binding domain, a polynucleotide comprising a customized spacer region, a polynucleotide comprising a transmembrane domain, and a polynucleotide comprising an intracellular signaling domain. It has been surprisingly found that the length of the spacer region can affects the ability of chimeric receptor modified T cells to recognize target cells in vitro and affects in vivo efficacy of the chimeric receptor modified T cells. Pharmaceutical formulations produced by the method, and methods of using the same, are also described.
    Type: Grant
    Filed: November 17, 2017
    Date of Patent: August 11, 2020
    Assignees: Fred Hutchinson Cancer Research Center, Seattle Children's Hospital
    Inventors: Michael C. Jensen, Stanley R. Riddell, Michael Hudecek
  • Publication number: 20200237827
    Abstract: The use of luteinizing hormone receptor (LHR) binding agents and luteinizing hormone (LH) agonists to enrich for primitive hematopoietic stem cell (pHSC) populations, to target pHSC for ablation, and/or to expand pHSC populations are described. The methods can be used to prepare therapeutic hematopoietic stem cell (HSC) populations, to prepare patients for therapeutic HSC transplants, and/or to treat malignancies, such as those associated with hyperproliferative HSC.
    Type: Application
    Filed: October 2, 2018
    Publication date: July 30, 2020
    Applicants: Fred Hutchinson Cancer Research Center, Memorial Sloan Kettering Cancer Center
    Inventors: Jarrod Dudakov, Marcel van den Brink, Enrico Velardi, Hans-Peter Kiem, Stefan Radtke, Scott James
  • Patent number: 10726101
    Abstract: Various embodiments of the present disclosure comprise methods, apparatus, systems and software for use in implementing acceptance and commitment therapy (ACT). The methods include notifying or reminding users to track completion of exercises, and to track and/or monitor awareness of urges and the number of times the user allows urges to pass. Also, physical sensors can be employed to help monitor the user's detrimental behaviors and to send notifications or reminders to the user to perform exercises or track urges.
    Type: Grant
    Filed: February 9, 2015
    Date of Patent: July 28, 2020
    Assignee: FRED HUTCHINSON CANCER RESEARCH CENTER
    Inventor: Jonathan Bricker
  • Patent number: 10702551
    Abstract: The present disclosure provides compositions and methods for the delivery of immune cells to treat un-resectable or non-resected tumor cells and tumor relapse. The compositions comprise (i) a structure comprising an injectable polymer or scaffold comprising pores; (ii) lymphocytes disposed within the structure, (iii) at least one lymphocyte-adhesion moiety associated with the structure; and (iv) at least one lymphocyte-activating moiety associated with the structure, and optionally an immune stimulant.
    Type: Grant
    Filed: October 9, 2018
    Date of Patent: July 7, 2020
    Assignee: FRED HUTCHINSON CANCER RESEARCH CENTER
    Inventor: Matthias Stephan
  • Publication number: 20200199534
    Abstract: Therapeutic formulations containing CD34+ stem cells derived from negative selection are described. The cells within the formulations can be genetically-modified for a number of therapeutic purposes. The disclosure is particularly useful for the treatment of patients with fragile stem cells or stem cells with low CD34+ expression levels.
    Type: Application
    Filed: April 27, 2018
    Publication date: June 25, 2020
    Applicant: Fred Hutchinson Cancer Research Center
    Inventors: Jennifer E. Adair, Hans-Peter Kiem
  • Patent number: 10690651
    Abstract: The invention disclosed herein generally relates to methods and kits for diagnosing, assessing disease risk, treating, and preventing bacterial vaginosis (BV) and associated conditions. Additional embodiments include methods for developing metabolic profiles associated with increased disease risk, and developing new approaches to treat BV based on interrupting metabolic networks.
    Type: Grant
    Filed: April 13, 2016
    Date of Patent: June 23, 2020
    Assignee: FRED HUTCHINSON CANCER RESEARCH CENTER
    Inventors: Sujatha Srinivasan, David N. Fredricks
  • Publication number: 20200190220
    Abstract: Circular handed alpha-helical repeat proteins are described. The repeat proteins have a number of uses as scaffolds for geometrically precise, arrayed presentation of cell-signaling or immune-related protein and peptide epitopes, as well as numerous other therapeutic, diagnostic, and nanotechnological uses.
    Type: Application
    Filed: February 26, 2020
    Publication date: June 18, 2020
    Applicant: Fred Hutchinson Cancer Research Center
    Inventors: Philip Bradley, Barry L. Stoddard
  • Patent number: 10676746
    Abstract: The present invention provides methods for treating cancers having a mutation in one or more tumor suppressor genes, comprising providing to a subject in need thereof an inhibitor of a kinase, as well as related methods and compositions.
    Type: Grant
    Filed: November 21, 2014
    Date of Patent: June 9, 2020
    Assignee: Fred Hutchinson Cancer Research Center
    Inventors: Christopher Kemp, Carla Grandori, Eduardo Mendez, Russell Moser, Chang Xu
  • Publication number: 20200164059
    Abstract: Anti-Epstein Barr Virus (EBV) antibodies and vaccines are described herein. The antibodies and vaccines can be used to treat and/or reduce the risk of EBV infection and to treat and/or reduce the risk of complications associated with EBV infection, such as infectious mononucleosis, lymphoproliferative disorders, carcinomas, and smooth muscle tumors.
    Type: Application
    Filed: May 10, 2018
    Publication date: May 28, 2020
    Applicant: Fred Hutchinson Cancer Research Center
    Inventor: Andrew McGuire
  • Publication number: 20200164060
    Abstract: Herpes Simplex Virus type 2 (HSV-2) epitopes bound by CD8 or CD4 tissue resident memory cells at a healed site of HSV-2 infection are disclosed. The HSV-2 epitopes can be used as immunogenic compositions to elicit protective immune responses against HSV-2.
    Type: Application
    Filed: July 20, 2018
    Publication date: May 28, 2020
    Applicants: Fred Hutchinson Cancer Research Center, University of Washington
    Inventors: David Koelle, Anna Wald, Christine Johnston, Christine Posavad, Larry Corey
  • Patent number: 10653756
    Abstract: This invention provides, among other things, methods for the identification and isolation of viable putative long-lived antigen-specific memory CD8+ T cell subsets (CMhi and EMhi) with high surface expression of CD161 and/or IL-18R? and the capacity to rapidly efflux the fluorescent dye Rh123.
    Type: Grant
    Filed: February 23, 2018
    Date of Patent: May 19, 2020
    Assignee: Fred Hutchinson Cancer Research Center
    Inventors: Cameron J. Turtle, Stanley R. Riddell
  • Publication number: 20200148767
    Abstract: Anti-CD33 antibodies are described. The anti-CD33 antibodies can bind within the V-set Ig-like domain or the C2-set Ig-like domain of CD33. Epitopes on the C2-set Ig-like domain can provide a “pan-binding” site, to which the cognate antibody will bind regardless of whether the CD33 molecule also contains the V-set domain (as in, for example, CD33FL) or not (as in, for example, CD33?E2). Alternative epitopes on the C2-set Ig-like domain are accessible for binding if the V-set domain is absent (e.g., as in CD33?E2). Antibodies that bind an epitope on the C2-set Ig-like domain (whether they exhibit pan or V-set absent binding) are directed at novel therapeutic targets and can increase therapeutic efficacy against CD33-related disorders. Also described are molecules comprising a binding-competent domain from at least one described anti-CD33 antibody, including scFvs, bi-specific antibody molecules, chimeric antigen receptors, and immunoconjugates. Methods of use are also provided.
    Type: Application
    Filed: May 25, 2018
    Publication date: May 14, 2020
    Applicant: Fred Hutchinson Cancer Research Center
    Inventors: Roland B. Walter, Christopher Mehlin, George S. Laszlo, Colin E. Correnti